Eli Lilly and Co. revealed promising data from a Phase 3 trial evaluating its oral GLP-1 receptor agonist. The study demonstrated the pill's effectiveness in managing blood sugar levels in adults with type 2 diabetes and promoting weight reduction.
GLP-1 medications have become increasingly popular for their dual benefits in diabetes management and weight loss. Currently, most GLP-1 drugs are administered via injection. An oral option could significantly improve patient convenience and adherence.
The company plans to submit the trial data to regulatory agencies, seeking approval to market the oral GLP-1 pill. If approved, it would provide a new treatment option for millions living with type 2 diabetes and obesity. Further details on the trial's specific outcomes and potential side effects will be released at an upcoming medical conference.
Eli Lilly's Oral GLP-1 Pill Shows Promise in Diabetes, Weight Loss
Eli Lilly and Co. has announced positive results from a Phase 3 clinical trial of its experimental oral GLP-1 medication. The once-daily pill is designed to treat type 2 diabetes and aid in weight loss. This new development offers a potential alternative to injectable GLP-1 drugs like Zepbound and Mounjaro, also produced by Eli Lilly.
Source: Read the original article at CBS